Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq analysis of knockdown of ANXA2 in uterine carcinosarcoma cell line FU-MMT-1 cells.

ABSTRACT: Uterine carcinosarcomas (UCS) are rare highly aggressive gynecological malignancy. ANXA2 is a calcium-dependent phospholipid binding protein that is over-expressed in various cancers, and plays a pivotal role in tumor migration, metastasis. However, the exact function and mechanism of ANXA2 in UCS have not been elucidated. Herein, we aim to elucidate the role of ANXA2 in UCS and the molecular mechanism involved in it.

ORGANISM(S): Homo sapiens

PROVIDER: GSE241829 | GEO | 2024/08/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Whole-genome DNA methylation profiling identifies epigenetic signatures of uterine carcinosarcoma

Project description:Uterine carcinosarcoma (UCS) is a form of endometrial cancer simultaneously exhibiting carcinomatous and sarcomatous elements, but the underlying molecular and epigenetic characteristic of this disease is poorly understood. We generated complete DNA methylomes for both the carcinomatous and the sarcomatous components of three UCS samples separated by laser capture microdissection and compared DNA methylomes of UCS with that of normal endometrium as well as methylomes derived from endometrioid carcinoma, serous endometrial carcinoma, and endometrial stromal sarcoma. We identified epigenetic lesions specific to carcinosarcoma, and specific to two components. Hallmarks of DNA methylation abnormality of UCS included global hypomethylation, especially in repetitive elements, and hypermethylation of tumor suppressor gene promoters. Among these, aberrant DNA methylation of MIR200 genes is a key feature of UCS. The carcinoma component of UCS was characterized by hypermethylation of promoters of EMILIN1, NEFM and CLEC14A, genes that are associated with tumor vascularization. In contrast, DNA methylation changes of PKP3, FAM83F and TCP11 were more characteristic of the sarcoma components. Our findings highlight the epigenetic signatures that distinguish the two components of UCS, providing a valuable resource for investigation of these diseases.

2017-03-08 | GSE86505 | GEO

RNA-seq analysis of knockdown of ANXA2 in uterine carcinosarcoma cell line FU-MMT-1 cells.

Project description:RNA-seq analysis of knockdown of ANXA2 in uterine carcinosarcoma cell line FU-MMT-1 cells.

| PRJNA1010199 | ENA

A novel tsRNA, m7G-3' tiRNA LysTTT, promotes bladder cancer malignancy via regulating ANXA2 phosphorylation

Project description:Emerging evidence indicates that tRNA-derived small RNAs (tsRNAs) with the most abundant RNA modifications play an important role in many complex physiological and pathological processes. However, the biological function and regulation mechanism of modified tsRNA in cancer are still poorly understood. Here, we screened and confirmed a novel m7G modified tsRNA, m7G-3'tiRNA LysTTT (mtiRL) in a variety of chemical carcinogenic models by combined small RNA sequencing with m7G small RNA modified Chip. Moreover, we found that mtiRL catalyzed by tRNA m7G modifying enzyme mettl1 promoted bladder cancer malignancy in vitro and in vivo. Mechanistically, mtiRL specifically bound to oncoprotein Annexin A2 (ANXA2) to promote Tyr24 phosphorylation of ANXA2 by enhancing interactions between ANXA2 and YES1, leading to ANXA2 activation and increased ANXA2 nuclear distribution in bladder cancer cells. Together, these findings define a critical role for mtiRL, targeting this novel m7G modified tsRNA would be an efficient way for the treatment of BC.

2024-05-11 | GSE232579 | GEO

RNA-seq analysis of transcriptomes in Wild Type and ANXA2 knockdown HK2 cells

Project description:We conducted this experiment to study the effects of Annexin A2 (ANXA2) on gene expression in human proximal tubular epithelial (HK2) cells in vitro. Short hairpin RNA targeting ANXA2 was designed and cloned into vector pGFP-B-RS for RNAi to generate the recombinant expression plasmids, which were transfected into HK2 cells. RNA-seq analysis were performed on HK2 cells, with or without ANXA2 knockdown, to reveal the differentially expressed genes (DEGs) and regulated alternative splicing events (RASEs). Then the DEGs and RASEs were validated by qRT-PCR. Using criteria of an absolute fold change of ≥2.0 or ≤ 0.5 and false discovery rate (FDR) of < 0.05 with the edgeR package, RNA-seq analysis of the transcriptomes revealed 220 upregulated and 171 downregulated genes related to ANXA2 knockdown.

2022-06-16 | GSE159360 | GEO

Effect of depletion of ANXA2 and ANXA5 on gene expression in primary murine mesenchymal stromal cells

Project description:To investigate the effects of ANXA2 or ANXA5 depletion on gene expression in primary mesenchymal stromal cells we compared the gene expression profile of sorted mesenchymal stromal cells from the bone marrow of normal wildtype, ANXA2 knockout or ANXA5 knockout mice.

2022-06-14 | GSE205762 | GEO

Effect of depletion of Anxa2 on gene expression during Oxygen-glucose deprivation and reoxygenation of BV2 microglia cells

Project description:To investigate the function Anxa2 in the regulation of immune inflammation after Oxygen-glucose deprivation and reoxygenation, we established BV2 microglia cells in Anxa2 has been knocked down by shRNA.

2024-02-10 | GSE223540 | GEO

Aberrant expression of TRIM24 develops carcinosarcoma in vivo: a relevant model to study human metaplastic breast cancer

Project description:To identify chromatin accessibility in TRIM24-driven carcinosarcomas, we performed ATAC-Seq in primary cell line derived from TRIM24-driven mouse model.

2021-06-21 | GSE149685 | GEO

Integrated Molecular Characterization of Uterine Carcinosarcoma.

Project description:We performed genomic, epigenomic, transcriptomic, and proteomic characterizations of uterine carcinosarcomas (UCSs). Cohort samples had extensive copy-number alterations and highly recurrent somatic mutations. Frequent mutations were found in TP53, PTEN, PIK3CA, PPP2R1A, FBXW7, and KRAS, similar to endometrioid and serous uterine carcinomas. Transcriptome sequencing identified a strong epithelial-to-mesenchymal transition (EMT) gene signature in a subset of cases that was attributable to epigenetic alterations at microRNA promoters. The range of EMT scores in UCS was the largest among all tumor types studied via The Cancer Genome Atlas. UCSs shared proteomic features with gynecologic carcinomas and sarcomas with intermediate EMT features. Multiple somatic mutations and copy-number alterations in genes that are therapeutic targets were identified.

| S-EPMC5599133 | biostudies-literature

Role of TGF-? signaling in uterine carcinosarcoma.

Project description:Uterine carcinosarcomas (UCS) are rare (3-4%) but highly aggressive, accounting for a disproportionately high (16.4%) mortality among uterine malignancies. Transforming growth factor beta (TGF?) is a multifunctional cytokine that regulates important cellular processes including epithelial-mesenchymal transition (EMT). Existence of biphasic elements and a report demonstrating amplification of TGF? at 19q13.1 prompted us to investigate the role of TGF? signaling in UCS.Here we demonstrated the components of TGF? pathway are expressed and functional in UCS. TGF?-I induced significant Smad2/3 phosphorylation, migration and EMT responses in UCS cell lines which could be attenuated by the TGF? receptor I (TGF?R-I) or TGF? receptor I/II (TGF?R-I/II) inhibitor developed by Eli Lilly and company. Importantly, TGF?-I induced proliferation was c-Myc dependent, likely through activation of cell cycle. c-Myc was induced by nuclear translocation of nuclear factor of activated T cells (NFAT-1) in response to TGF?-I. Inhibition of NFAT-1 or TGF?R-I blocked c-Myc induction, cell cycle progression and proliferation in UCS. In corroboration, mRNA levels of c-Myc were elevated in recurrent versus the non-recurrent UCS patient samples. Interestingly, in the absence of exogenous TGF? the TGF?R-I/II inhibitor enhanced proliferation likely through non-Smad pathways. Thus, inhibition of TGF?R-I could be efficacious in treatment of UCS.

| S-EPMC4546494 | biostudies-literature

Targeting the TGF? pathway in uterine carcinosarcoma.

Project description:Uterine carcinosarcoma (UCS) is a relatively infrequent, but extremely aggressive endometrial malignancy. Although surgery and chemotherapy have improved outcomes, overall survival (OS) remains dismal due to the lack of targeted therapy and biphasic (epithelial and mesenchymal) nature that renders the tumor aggressive and difficult to manage. Here we report a role of transforming growth factor-? (TGF?) in maintaining epithelial to mesenchymal transition (EMT) phenotype and aggressiveness in UCS. Using a 3D-culture system, we evaluated the efficacy of the transforming growth factor-? receptor-I (TGF?R1) kinase inhibitor Galunisertib (GLT), alone and in combination with standard chemotherapeutic drugs used for the management of UCS. We demonstrate that GLT by inhibiting canonical and non-canonical signaling emanating from transforming growth factor-?1 (TGF?1) reduces cellular viability, invasion, clonal growth and differentiation. Interestingly, GLT sensitizes UCS cells to chemotherapy both in vitro and in in vivo preclinical tumor model. Hence, targeting TGF? signaling, in combination with standard chemotherapy, may be exploited as an important strategy to manage the clinically challenging UCS.

| S-EPMC7590842 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data